Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Authors
Trněný, MLamy, T
Walewski, J
Belada, D
Mayer, J
Radford, John A
Jurczak, W
Morschhauser, F
Alexeeva, J
Rule, S
Afanasyev, B
Kaplanov, K
Thyss, A
Kuzmin, A
Voloshin, S
Kuliczkowski, K
Giza, A
Milpied, N
Stelitano, C
Marks, R
Trümper, L
Biyukov, T
Patturajan, M
Bravo, M
Arcaini, L
Affiliation
Department of Hematology, Charles University Hospital, Prague, Czech RepublicIssue Date
2016-03
Metadata
Show full item recordCitation
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial 2016, 17 (3):319 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(15)00559-8Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S1470204515005598Type
ArticleLanguage
enISSN
14702045ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00559-8